Effects of ipriflavone on bone remodeling in primary hyperparathyroidism.
The aim of this study was to evaluate the effects of ipriflavone treatment on bone remodeling in primary hyperparathyroidism. Nine patients, 6 females and 3 males (mean +/- SD age 56 +/- 12.5 years) were treated with 1200 mg/day of ipriflavone by oral administration divided in 3 daily doses. All patients were treated for 21 days; in 5 patients treatment was prolonged to 42 days. In all patients the main serum and urinary parameters of bone remodeling were evaluated. The results suggest that ipriflavone affects bone remodeling by inhibiting bone resorption without affecting bone formation. Ipriflavone is, therefore, indicated in the treatment of metabolic bone diseases characterized by a high bone turnover.
Mazzuoli
G
G
Cattedra di Medicina Interna, University of Rome, La Sapienza, Italy.
Romagnoli
E
E
Carnevale
V
V
Scarda
A
A
Scarnecchia
L
L
Pacitti
M T
MT
Rosso
R
R
Minisola
S
S
D000328:Adult; D000368:Aged; D016723:Bone Remodeling / Q000187:drug effects*; D002118:Calcium / Q000097:blood / Q000652:urine; D003404:Creatinine / Q000097:blood / Q000652:urine; D005260:Female; D006801:Humans; D006909:Hydroxyproline / Q000097:blood; D006961:Hyperparathyroidism / Q000188:drug therapy* / Q000503:physiopathology; D007529:Isoflavones / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D015675:Osteocalcin / Q000097:blood; D010758:Phosphorus / Q000097:blood
D007529:Isoflavones; D015675:Osteocalcin; D010758:Phosphorus; C018986:ipriflavone; D003404:Creatinine; D006909:Hydroxyproline; D002118:Calcium